DVA sentiment intelligence

What You Need To Know Ahead of DaVita’s Earnings Release

DaVita Inc. (DVA), a kidney care provider, is set to announce its Q2 FY2026 results, with analysts expecting diluted EPS of $4.01, a significant increase from the previous year. The company's stock has significantly outperformed the S&P 500 and the healthcare sector year-to-date,

Tone

Positive 75/100

Event

Earnings

Published

15 Jul 2026 08:38

Source

inkl

Healthcare stocks gain favor as State Street up...

Tone

Positive 66/100

Event

Market update

Published

14 Jul 2026 22:37

Source

Pluang

Truist Raises Price Target on DaVita to $250 From $205, Keeps Hold Rating

Truist has increased its price target for DaVita (DVA) shares from $205 to $250, while maintaining a "Hold" rating on the stock. This adjustment comes amidst recent analyst activities, including UBS raising its price target to $270 and Barclays to $218. DaVita specializes in dial

Tone

Positive 65/100

Event

Analyst action

Published

14 Jul 2026 11:37

Source

marketscreener.com

DaVita Inc. stock outperforms competitors on strong trading day

Shares of DaVita Inc. (DVA) rose 1.19% to $235.58 on Monday, outperforming the S&P 500 Index and Dow Jones Industrial Average, which both saw declines. This marks the stock's second consecutive day of gains despite a dismal overall trading session for the market.

Tone

Positive 71/100

Event

Market update

Published

13 Jul 2026 17:12

Source

MarketWatch

DaVita Inc. (DVA) Stock Analysis: Strong ROE And Growth Potential In Healthcare Sector

Tone

Positive 82/100

Event

Market update

Published

13 Jul 2026 09:18

Source

DirectorsTalk Interviews

DaVita stock holds steady as kidney care specialist focuses on operations and long-term dialysis dem

DaVita Inc. (ISIN US23918K1088) maintains a steady stock performance due to its essential role in US kidney care and dialysis services, serving an aging population with chronic kidney disease. The company's business model relies on a recurring revenue base from dialysis treatment

Tone

Positive 64/100

Event

Earnings

Published

13 Jul 2026 09:46

Source

Ad Hoc News

Exciting News for Farmington: DaVita Maple Valley is Expanding!

DaVita Maple Valley in Farmington is expanding its dialysis shift options to provide greater flexibility and access to care for the community. To celebrate this expansion and showcase its services, the clinic is hosting a community open house on Tuesday, July 21st, from 2:00 PM t

Tone

Positive 74/100

Event

Market update

Published

12 Jul 2026 23:12

Source

Park Hills Daily Journal

DaVita stock reflects steady dialysis demand amid US healthcare focus

DaVita Inc. offers investors exposure to the U.S. dialysis and chronic kidney care market, driven by stable patient volumes and predictable cash flows. The company's business model relies on recurring treatments for end-stage renal disease, balancing clinical quality with regulat

Tone

Positive 71/100

Event

Balance sheet

Published

12 Jul 2026 02:34

Source

ad-hoc-news.de

3 Healthcare Stocks Investors Are Turning To As Growth Valuations Look Stretched

Tone

Positive 66/100

Event

Market update

Published

10 Jul 2026 19:07

Source

Sahm

DVA|DaVita Inc|Price:232.800|Chg%:+3.260

This article provides a comprehensive overview of DaVita Inc. (DVA), highlighting its stable fundamentals, high growth potential, and fair valuation within the Healthcare Providers & Services industry. It details the company's kidney care services, key financial figures, analyst

Tone

Positive 63/100

Event

Analyst action

Published

10 Jul 2026 18:07

Source

TradingKey

DaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says

UBS analysts project DaVita (DVA) can achieve a long-term volume growth rate of 2% by 2029, driven by an improving competitive landscape and increased focus on value-based care. The firm maintained a Buy rating on DVA. This optimistic outlook anticipates a recovery from recent ch

Tone

Positive 72/100

Event

Guidance

Published

10 Jul 2026 16:07

Source

Moomoo

DaVita stock holds steady as kidney care demand supports long term outlook

The article discusses DaVita Inc. (DVA), a leading provider of kidney dialysis services, and its stable business model driven by chronic treatment demand. It highlights how DaVita's stock performance is influenced by factors like reimbursement rules, labor costs, and regulatory s

Tone

Positive 75/100

Event

Guidance

Published

10 Jul 2026 12:10

Source

Ad Hoc News

UBS Adjusts Price Target on DaVita to $270 From $235

UBS has increased its price target for DaVita (DVA) to $270 from $235. This adjustment was published on July 10, 2026, at 06:39 am EDT by MT Newswires. DaVita Inc. specializes in providing dialysis services, operating centers in the United States and internationally.

Tone

Positive 71/100

Event

Analyst action

Published

10 Jul 2026 10:39

Source

marketscreener.com

DAVITA INC. : BARCLAYS RAISES TARGET PRICE TO $218 FROM $194

Barclays has increased its target price for DaVita Inc. (DVA) shares to $218 from $194. This adjustment reflects a more optimistic outlook on the company's future performance by the analyst firm. Investors may view this as a positive signal for DaVita's stock.

Tone

Positive 72/100

Event

Analyst action

Published

10 Jul 2026 09:07

Source

Moomoo

DaVita Inc focus on kidney care operations as investors watch US healthcare demand

DaVita Inc. (DVA) focuses on providing kidney care services, particularly dialysis, in the complex U.S. healthcare system. Investors are closely monitoring the company's operational efficiency, reimbursement dynamics, and patient outcomes within this highly regulated market. The

Tone

Positive 62/100

Event

Macro sensitivity

Published

09 Jul 2026 11:48

Source

Ad-hoc-news.de

Barclays Adjusts Price Target on DaVita to $218 From $194

Barclays has increased its price target for DaVita (NYSE: DVA) from $194 to $218, maintaining an Overweight rating on the stock. This adjustment reflects Barclays' updated outlook on the company's valuation.

Tone

Positive 75/100

Event

Analyst action

Published

08 Jul 2026 22:40

Source

Moomoo

DaVita Inc. focuses on core dialysis services as investors watch U.S. healthcare trends

DaVita Inc. is a leading provider of kidney care services in the U.S., operating a large network of outpatient dialysis centers. The company's business is closely tied to long-term healthcare demand and reimbursement dynamics, and it focuses on standardized clinical protocols and

Tone

Positive 64/100

Event

Macro sensitivity

Published

08 Jul 2026 16:15

Source

AD HOC NEWS

DaVita Inc. on Track for Record High Close -- Data Talk

This article from "Data Talk" reports that DaVita Inc. is on track for a record high close. It suggests positive financial performance for the company.

Tone

Positive 92/100

Event

Market update

Published

08 Jul 2026 14:37

Source

Moomoo

DaVita (DVA) Q2 2024 earnings summary

DaVita reported strong Q2 2024 results, with consolidated revenues of $3.19 billion and adjusted operating income of $506 million, surpassing expectations due to lower patient care costs and improved revenue per treatment. Despite volume growth lagging due to severe weather and h

Tone

Positive 75/100

Event

Earnings

Published

08 Jul 2026 07:07

Source

Quartr

The DaVita In-Center Hemodialysis - A core service tailored to U.S. kidney patients

This article details DaVita's In-Center Hemodialysis service, a core offering for End-Stage Kidney Disease patients in the U.S. It describes the treatment process, DaVita's extensive clinic network, and the multidisciplinary care teams involved. The piece also touches on regulato

Tone

Positive 67/100

Event

Market update

Published

08 Jul 2026 02:06

Source

AD HOC NEWS